» Articles » PMID: 23926550

Effect of Pre-ovulatory Single Dose GnRH Agonist Therapy on IVF Outcome in GnRH Antagonist Cycles; A Prospective Study

Overview
Date 2013 Aug 9
PMID 23926550
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of present study was to evaluate the role of pre-ovulatory GnRH agonist therapy on IVF outcomes in GnRH antagonist cycles.

Methods: In this prospective study we recruited 100 infertile women undergoing IVF cycles with GnRH antagonists. The patients were assigned to two groups: Group A (the study group, n = 42) were assigned for receiving hCG + triptorelin for the final oocyte maturation and group B (the control group, n = 58) were assigned for only hCG. The t-test, chi-square (χ(2)), and Fisher's exact test were used for data analysis. A p < 0.05 was taken as statistically significant. The results are presented by mean± SD, and in percents (%).

Results: LH levels significantly (p < 0.001) increased in the study group on the day of oocyte retrieval. All embryological parameters including the number of mature oocytes, fertilization and cleavage rates, number of high quality embryos and number of cases whose embryos were frozen were non-significantly higher in the study group. There were small but non-significant improvements in the clinical pregnancy, ongoing pregnancy, live birth and implantation rates in the study group.

Conclusion: Administering a single dose of GnRH agonist before oocyte retrieval in antagonist cycles may be helpful in improving the pregnancy rate but the results need to be verified in a larger trials.

Citing Articles

Ectopic pregnancy secondary to in vitro fertilisation-embryo transfer: pathogenic mechanisms and management strategies.

Refaat B, Dalton E, Ledger W Reprod Biol Endocrinol. 2015; 13:30.

PMID: 25884617 PMC: 4403912. DOI: 10.1186/s12958-015-0025-0.


Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.

Youssef M, van der Veen F, Al-Inany H, Mochtar M, Griesinger G, Mohesen M Cochrane Database Syst Rev. 2014; (10):CD008046.

PMID: 25358904 PMC: 10767297. DOI: 10.1002/14651858.CD008046.pub4.

References
1.
Pirard C, Donnez J, Loumaye E . GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006; 21(7):1894-900. DOI: 10.1093/humrep/del072. View

2.
Al-Inany H, Abou-Setta A, Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006; (3):CD001750. DOI: 10.1002/14651858.CD001750.pub2. View

3.
Tesarik J, Hazout A, Mendoza C . Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004; 19(5):1176-80. DOI: 10.1093/humrep/deh235. View

4.
Rackow B, Kliman H, Taylor H . GnRH antagonists may affect endometrial receptivity. Fertil Steril. 2008; 89(5):1234-1239. PMC: 2699407. DOI: 10.1016/j.fertnstert.2007.04.060. View

5.
Schachter M, Friedler S, Ron-El R, Zimmerman A, Strassburger D, Bern O . Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2007; 90(4):1087-93. DOI: 10.1016/j.fertnstert.2007.07.1316. View